• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Restoring sight to the blind: A conversation with Second Sight’s Robert Greenberg

Restoring sight to the blind: A conversation with Second Sight’s Robert Greenberg

November 21, 2013 By Brian Johnson

Restoring sight to the blind: Second Sight's Robert Greenberg

Second Sight Medical’s Argus II "bionic eye" is likely the most talked-about medical device of 2013.

The retinal prosthesis, approved by the FDA last summer, isn’t slated to hit the market until 2014, but the buzz around the device is already at a fever pitch.

The Argus II was hailed as one of the top inventions of the year by Time and Popular Science magazines and named the top innovation for 2014 by the Cleveland Clinic.

In a recent chat with Second Sight’s founder & CEO, Dr. Robert Greenberg, he told MassDevice.com about the technology behind the Argus II, the journey to restore sight to the blind and how a 1970s television show helped influence 1 of the greatest inventions of our time.

Interesting in hearing Greenberg’s story in person? He’ll be our guest at the 2013 MassDevice Big 100 West Dec. 10 in Irvine, Calif. Learn more by visiting our website.

Hear the story behind the bionic eye: Register for the Big 100 West

MassDevice: After more than 20 years working intimately with the construction of the eye, what do you find most fascinating about this organ?

Dr. Robert Greenberg: What drove me to go to medical school was the sheer wonder of, and trying to understand, how the body works. It’s such an intricate machine, far better engineering than any [man-made] machine could ever be.

Part of what I learned in medical school that I thought was interesting was the retina, the back of the eye, which changes light into chemical signals, that retina is backwards from the way you would engineer it.

The light comes through the front of the eye, all the way through the retina and strikes the photoreceptors, the cells that are actually picking up the light and changing it to signals in the back of the brain, which are all the way at the bottom. I’ve always wondered why that was. I’ve never heard a great explanation, but I’m sure there’s something that at some point we’ll discover why it works that way.

Hear the story behind the bionic eye: Register for the Big 100 West

These photoreceptors in the patients we’re treating are degenerating and they no longer change the light into electrical signals, so we are trying to do that for them.

We’ve taken modern technology of a video camera and we’re piping the information from the video camera into electrodes. In essence, we’re trying to trick those cells into thinking the electrical signals are coming from the body’s natural photoreceptors. So we try to mimic them as closely as possible, but we’re not doing it at the level of sophistication that the body does yet.

For example, a normal eye has 1 million photoreceptors; in our current commercialized device, we have 60 electrodes. With those we can create life-changing vision for these patients, but we’re still a long way to go from having normal vision.

Greenberg

MassDevice: Second Sight has really captured the attention of the world. What do you attribute that to?

Greenberg: I think there’s a combination of reasons the Argus II has captured people’s attention. One is that we can all relate to what it’s like to be blind by just closing our eyes. I think people with sight can all appreciate the impact that losing our vision would have on our lives.

Our challenge did turn out to be a very significant challenge. There are lots of folks around the world trying to do similar things, but it turned out to be a more significant task than we had anticipated. It took us more than 20 years and more than $200 million in investment to solve the various problems.

MassDevice: There’s something about the Argus II device that looks a little like science fiction. I’m curious, are you a fan of science fiction, or were the people who designed the device fans? Was there some influence from movies or television shows that made its way into the creation of the device?

Greenberg: There’s no doubt. I grew up in the 1970s watching "The $6 Million Man," and that definitely piqued my interest. In fact, it was probably the reason I got into biomedical engineering in general, was that television show and the idea that you could not only restore body parts but actually create a better human. There were many of us at the company who were influenced by that show in particular.

MassDevice: So it must be really cool when you see the Argus II being used by the Smithsonian Channel in their Bionic Man television show?

Greenberg: I have. Unfortunately we’re not the bionic eye of the $6 Million Man yet. The other thing I laugh about is the idea that you could do all the things they accomplished on that show with just $6 million.

MassDevice: Yeah, they were about $194 million short just for the eyes.

Greenberg: Exactly, and our eye doesn’t have the superhuman characteristics of the show.

Hear the rest of the story at the Big 100 West

MassDevice: Is the bionic prosthesis really the best way to treat blindness?

Greenberg: I think in the near term – over the next 20 years – artificial bionic eyes or retinal prostheses are the most likely to restore meaningful vision to patients.

Longer-term, I would hope stem cells and genetic therapies would advance to where we could fix the underlying disease. With these implants, we’re not fixing the disease, we’re bypassing the damaged part. That’s a good stop-gap, but someday I hope we’ll be able to fix the underlying disease. But that’s a much bigger step and there’s a lot of work before it can be a commercially viable treatment.


Filed Under: News Well, Optical/Ophthalmic Tagged With: MassDevice Big 100 Regional Roundtable, second-sight-medical

In case you missed it

  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive
  • MedTrace Pharma moves forward on 15 O-water imaging tech
  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS